496 results about "Clinical significance" patented technology

A system supports creation and modification of a flexible and comprehensive location structure model able to track patients in a healthcare (or other) setting and identify suitable patient locations and location availability via a user friendly display interface. A method processes location related information for use in facilitating movement of a patient in a healthcare enterprise. The method involves establishing a profile comprising information identifying multiple locations available to accommodate a patient for different purposes. The profile incorporates attributes including a location type identifier, and a location characteristic of clinical significance influencing availability of a particular location to a patient having a particular medical condition. The profile is employed in providing a user with an indication of location availability in response to user command.

A clinical data processing system systematically organizes and analyzes clinically significant information of a patient using a result flag indicating a critical or abnormal result to automate display of a view of clinical data in various contexts including diagnosis, insurance, medical complaint assessment and others to improve patient care. A system for use in processing patient clinical data for access by a user includes a repository associating an observation with a clinical significance indicator and with data indicating observations relevant to evaluation of the observation having the associated clinical significance indicator. A clinical data processor uses the repository fork automatically providing data for display in response to receiving data representing an input observation and an associated clinical significance indicator. The data for display supports a user in making a patient assessment and includes the input observation and associated relevant clinical data item,s. A display processor initiates generation of data representing an image including the data for display.

A cartilage therapeutic composition is developed for clinical transplantation into articulatio genu (knee joints) or ankle joints. It has clinical significance for symptomatic cartilage defects of the femoral condyle (medial, lateral, or trochlear) and bone cartilage defects of the talus (anklebone) in human or animal hosts, The cartilage therapeutic composition comprises a mixture of components of chondrocytes isolated and expanded or differentiated from a host such as a human or animal, and thrombin and a fibrinogen matrix containing fibrinogen. An application of the cartilage therapeutic composition is that a mixture of thrombin, chondrocyte components and a fibrinogen matrix is injected into a cartilage defect region followed by solidification therein. It provides rapid healing and effective regeneration of cartilage without surgical operation. It has the merits of safety and simplicity by allowing the use of an arthroscope for transplantation.

The radio remote electrocardiac monitoring system of the present invention consists of three parts including patient's electrocardiac monitoring instrument, monitoring center in the hospital and public communication network for connection. The communication method between the monitoring instrument and the monitoring center is one client terminal/server system, in which the monitoring instrument is radio accessed via GPRS to Internet for data communication with the monitoring center and can store the acquired electrocardiogram and transmit it via USB interface to computer. The system adopts triple monitoring capable of obtaining most of the electrocardiac for clinical use, possesses both dynamic electrocardiac monitoring function and radio remote electrocardiac monitoring function, makes it possible to lower the death rate of heart disease patients and has important clinical significance on early diagnosis of heart disease.

The invention discloses a retinal vessel segmentation method of a fundus image based on a classification and regression tree and AdaBoost. The method comprises the step of: constructing a 36-dimensinal feature vector including a local feature, a morphological feature and a pixel vector field divergence feature for each pixel point in the fundus image, so as to determine whether the pixel point is on a vessel. During classified calculation, the classification and regression tree is used as a weak classifier, so as to classify a sample set, then an AdaBoost classifier is trained, so as to obtain a strong classifier, and thus, the classified determination of each pixel point is completed, so as to obtain final segmentation results. The method has the advantages that a vessel trunk is preferably extracted, great advantages are taken to treat high-brightness focal areas, later treatment is facilitated and visual results are provided for main vessel diseases, and the method is suitable for computer aided quantitative analysis of the fundus image and disease diagnosis and has obvious clinical significance in auxiliary diagnosis of related diseases.

The invention discloses a tumor cloning mutation detection method and device based on next-generation sequencing and a memory medium. The method provided by the invention comprises the steps of carrying out mutation detection on a comparison file of paired tumor and normal samples through utilization of mutation detection software, computing a mutation frequency, and selecting segments with high sequencing quality as a statistics result; carrying out copy number and purity detection on the paired tumor and normal samples through utilization of purity detection software; combining small segments into big segments, and annotating the copy number in a mutation area; and computing a proportion of the mutation in a tested tumor tissue through utilization of a beta distribution model according to tumor sample purity and copy number detection results, thereby judging a tumor cloning mutation type. According to the method provide by the invention, influences of the sample purity and multiploidon the detection are avoided, the mutation type detection is relatively accurate, the subcloning mutation with clinical significance can be effectively identified, and the foundation for accurately and deeply researching a tumor cloning evolution process and searching a tumor therapy molecular mechanism is laid.

The invention discloses a differentially expressed gene identification method based on combined constraint non-negative matrix factorization. The method comprises the following steps of 1, representing a cancer-gene expression data set with a non-negative matrix X, 2, constructing a diagonal matrix Q and an element-full matrix E, 3, introducing manifold learning in the classical non-negative matrix factorization method, conducting orthogonal-constraint sparseness and constraint on a coefficient matrix G, and obtaining a combined constraint non-negative matrix factorization target function, 4, calculating the target function, and obtaining iterative formulas of a basis matrix F and the coefficient matrix G, 5, conducting semi-supervision non-negative matrix factorization on the non-negative data set X, and obtaining the basis matrix F and the coefficient matrix G after iteration convergence, 6, obtaining an evaluation vector (the formula is shown in the description), sorting elements in the evaluation vector (the formula is shown in the description) from large to small according to the basis matrix F, and obtaining differentially expressed genes, 7, testing and analyzing the identified differentially expressed genes through a GO tool. The identification method can effectively extract the differentially expressed genes where cancer data is concentrated, and be applied in discovering differential features in a human disease gene database. The identification method has important clinical significance for early diagnosis and target treatment of diseases.

The invention discloses a preparation method of an antibacterial biological activity ceramic coating with magnetic responsiveness, and belongs to the technical field of biological materials. The preparation method is combined with a layer-by-layer self-assembly technology by using ultrahigh adhesiveness of polydopamine so as to construct a coating of a multilayer film structure on the surface of a base material coated with a polydopamine film. A single layer film is prepared by coating polydopamine functionalized magnetic particle dispersion liquid, polydopamine functionalized antibacterial particle dispersion liquid or polydopamine functionalized biological activity ceramic particle dispersion liquid. The coating prepared through the preparation method has good biocompatibility, biological activity and antibacterial property, the coating can respond to an external magnetic field, and the effect of the external magnetic field can strengthen the osteoinductivity of the coating; the preparation method disclosed by the invention can effectively control the composition, thickness and shape of the coating according to actual requirements; the problems that the binding force between films formed by multilayer inorganic particles in the coating and the binding force between the coating and the base material are not strong are solved. The method has significant research value and clinical significance in bone tissue engineering.

The invention provides a turbidimetric rapid detection kit for myocardial infarction nano-immunoenhancement. The turbidimetric rapid detection kit comprises a reaction-detection integrated device, and a detection kit arranged in the reaction device, wherein a reagent R1, a reagent R2 and a calibrator are contained in the detection kit; simultaneously, quantitative detection for five important myocardial infarction-related biomarkers in one sample can be realized, and the five important biomarkers include content of troponin-I, content of D-dimer, content of myoglobin, content of hypersensitive C-reactive protein (hs-CRP) and content of heart-type fatty acid binding protein (FABP); and the turbidimetric rapid detection kit has an important clinical significance in the aspects of early diagnosis and disease course monitoring for myocardial infarction, treatment monitoring for medicines, and the like. The turbidimetric rapid detection kit provided by the invention realizes the integration of the reagents and the reaction device, and is simple, rapid and accurate to operate, high in sensitivity, strong in specificity, and low in detection cost; and the turbidimetric rapid detection kit is a detection/reagent measurement integrated kit suitable for outpatient and emergency treatment/clinical detection, and wide in instrument application range.

The invention discloses a crystalline lens biomechanics and optical property noninvasive in-vivo imaging system and a measuring method. The ultrasonic load system provides mechanical waves capable of enabling a crystalline lens to deform, a spectral domain OCT system achieves the structure and elastic imaging of the crystalline lens; on the basis of the yoke eliminating technology, OCT full-range imaging is achieved, full anterior segment two-dimensional or three-dimensional structure images from the anterior corneal surface to the retrolental surface, morphological and optical characteristic parameters of the crystalline lens are obtained through calculation, and a crystalline lens topographic map is constructed. Meanwhile, the phase sensitive OCT technology is utilized, strain distribution in the depth direction of the crystalline lens is obtained, and a two-dimensional or three-dimensional biomechanical characteristic distribution diagram of the crystalline lens is obtained through rebuilding. High-resolution imaging and precision measurement of biomechanics and optical properties of the crystalline lens provide the more comprehensive and complete imaging surveying basis for fundamental research, early diagnosis, operation plan formulating and postoperation result evaluation of cataract and other crystalline lens diseases, and the important practical significance and clinical significance are achieved.

The invention discloses an in situ hybridization probe, a reagent and an application of long non-coding RNA LOC401317. The long non-coding RNA LOC401317 can be used for preparing a prognosis preparation for a patient with nasopharyngeal carcinoma, and particularly a kit for predicting prognosis of the patient with the nasopharyngeal carcinoma employing an in situ hybridization detection method is prepared. A research proves that expression of the LOC401317 in a nasopharyngeal carcinoma tissue is lowered, and the patient with the nasopharyngeal carcinoma in low-expression LOC401317 is worse than the patient with the nasopharyngeal carcinoma in high-expression LOC401317 in prognosis, therefore, expression of the LOC401317 is applied to prognosis prediction of the patient with nasopharyngeal carcinoma; a powerful molecular biology basis can be provided for prognosis of the patient with the nasopharyngeal carcinoma; and the long non-coding RNA LOC401317 has profound clinical significance and important popularization and application prospects.

The invention provides a stem cell preparation for treating hepatic fibrosis, and a preparation method of the stem cell preparation. The stem cell preparation for treating hepatic fibrosis is prepared from human menstrual blood mesenchymal stem cells, a chemotactic factor CXCL8 and normal saline. The obtaining method of the menstrual blood mesenchymal stem cells is simple, free of ethical restriction, high in cell viability and high in proliferation capacity, has multi-directional differentiation potential and is simple and convenient to prepare. The menstrual blood mesenchymal stem cell preparation infusion technology provided by the invention is simple and convenient to operate; the hepatic fibrosis is treated by virtue of the menstrual blood mesenchymal stem cells; and the developed preparation method of the stem cell preparation for treating the hepatic fibrosis has very important clinical significance and wide application prospect.

A clinical data processing system systematically organizes and analyzes clinically significant information of a patient using a result flag indicating a critical or abnormal result to automate display of a view of clinical data in various contexts including diagnosis, insurance, medical complaint assessment and others to improve patient care. A system for use in processing patient clinical data for access by a user includes a repository associating an observation with a clinical significance indicator and with data indicating observations relevant to evaluation of the observation having the associated clinical significance indicator. A clinical data processor uses the repository for automatically providing data for display in response to receiving data representing an input observation and an associated clinical significance indicator. The data for display supports a user in making a patie nt assessment and includes the input observation and associated relevant clinical data items. A display processor initiates generation of data representing an image including the data for display.

The invention provides a circulating tumor cell detection kit and an application thereof. The circulating tumor cell detection kit is characterized by comprising a RosetteSep rare cell enriching reagent, an RNA (Ribonucleic Acid) extraction reagent, an RNA reverse transcription reagent, a fluorescence labeling Taqman probe, a specific primer and a qPCR (Quantitative Polymerase Chain Reaction) reaction system reagent. The kit can be applied to tumor patient minimally invasive liquid biopsy, early diagnosis and early warning on tumor metastasis and reappearance are achieved, the curative effect in antineoplaston and the tumor development situation are monitored, molecular subtyping based on circulating tumor cells is achieved, and sensitive medicines which specifically aim at the circulating tumor cells are selected, understanding about tumor metastasis, replase and relevant medicine resistance mechanisms is improved, and individualized treatment on tumor patients is guided, so that the total survival of tumor patients is remarkably improved, and great clinical significance is achieved.

The invention provides a composition and a kit for rapid and efficient extraction of a circulating unrelated nucleated cell from peripheral blood. The composition for rapid extraction of the circulating unrelated nucleated rare cell from the blood comprises buffer solution, hypotonic erythrocyte breaking solution, magnetic or non-magnetic immune micro-spheres coated with an anti-blood nucleated cell surface marker antibody and a cell separation medium with a certain density. Compared with the common commercial centrifugation medium on the market at present, the composition of the invention can greatly reduce the centrifugation time, and stably improve the cell recovery rate from original 60 plus or minus 20 percent to above 95 percent. When combined with the agent to remove leukocytes andhypotonic erythrocyte breaking means, the composition can be used for effectively and rapidly concentrating and extracting circulating unrelated nucleated rare cells in the peripheral blood, such as epithelial tumor cells and vascular endothelial cells. Therefore, the invention has great practical clinical significance for early diagnosis of tumors and heart diseases.

The invention provides an amphiphilic polymer with tumor targeting property and visible light degradability. The amphiphilic polymer has a structure shown in a formula (1), wherein R is long-chain alkyl with more than 8 carbon atoms; FA is folic acid; and x, y and z are natural numbers, x is more than 1 and less than 5, y is more than 3 and less than 15, and z is more than 1 and less than 3. A nano medicament carrier is obtained by self-assembling the polymer, hollow silicon spheres and a visible light response photo-sensitizer, wherein the photosensitizer is adsorbed to the anthraquinone group of the polymer through phi-phi conjugation; and the photosensitizer releases singlet oxygen under the irradiation of visible light, so that the hydrophobic group of the polymer is broken, the polymer is separated from the surfaces of the silicon spheres, and medicaments are released. The polymer and the medicament carrier can realize controlled release of the medicaments by using a visible light source with relatively low energy, the penetrability of the visible light in organisms is relatively high, and the medicament carrier has clinical significance for delivery and controlled release of anti-tumor medicaments.

The invention relates to a cardiac CT image-based coronary artery calcified plaque automatic detection method and belongs to the biomedical engineering technical field. According to the cardiac CT image-based coronary artery calcified plaque automatic detection method, on the basis of the three-dimensional reconstruction of cardiac CT images, the calcified plaques of coronary arteries are described and distinguished from different perspectives through a series of features; and the candidate calcified plaques of the coronary arteries are classified and quantified according to four stages, and therefore, the automatic detection of the calcified plaques can be realized. With the technology of the invention adopted, calcified plaques in a group of cardiac CT images can be automatically and quickly detected and measured, and coronary branches where the calcified plaques are located can be identified; the burden of labor force and errors caused by subjective factors can be effectively reduced; and the efficiency and accuracy of film reading can be improved. The method is of great clinical significance and enables considerable social and economic benefits.

The invention discloses a kit for detecting Hepassocin (HPS), which comprises an anti-Hepassocin antibody 1 and an anti-Hepassocin antibody 2, wherein the antibody 1 serves as a coating antibody, and the antibody 2 serves as a detection antibody. The kit disclosed by the invention has high sensitivity and high specificity and has a wide application prospect in the field of the quantitative detection of the HPS. The kit disclosed by the invention can be used for detecting liver injury related diseases, and also has certain clinical significance on diagnosis of liver cancer related diseases, cirrhosis related diseases and the like.

The invention discloses an application method of long no-coding RNA (Lnc RNA (Ribonucleic Acid)) RMST (Rhabdomyosarcoma 2 associated Transcript). The application method is used for preparing a prognosis preparation for glioma patients and particularly used for preparing a kit which is used for predicting the prognosis of the glioma patients by a real-time fluorescent quantitative analysis method. Confirmed by researches, the expression of Lnc RNA RMST in glioma tissue is increased, and the prognosis of the glioma patients with high Lnc RNA RMST expression is poorer than that of the glioma patients with low Lnc RNA RMST expression, so that by applying the expression of Lnc RNA RMST to the prognosis prediction of the glioma patients, a powerful basis for molecular biology can be provided for the prognosis of the glioma patients; the application method has far-reaching clinical significance and generalization performance.

Disclosed are a device, a system and a method for testing a heart motion function. A wearable intelligent perception technology is used to measure and perform fusion analysis on heart rate and motion of a measured person in real time, and a series of cardiopulmonary dynamic function digital indexes such as heart rate motion reaction capacity, a heart time varying index and exercise heart rate recovery are introduced. Compared with a cardiopulmonary motion test (CPX), the device, the system and the method for testing the heart motion function use the indexes distinct in index clinical significance and specific in normal reference value, are simple and convenient to use whenever and wherever possible, greatly reduce test risk, and have significance and application prospect for popularization in cardiopulmonary disease prevention and recovery.

The invention discloses a method for optimizing imaging parameters in a self-adaptive medical ultrasonic system and designs a method for improving the ultrasonic imaging quality by optimizing the sound velocity and the tissue sound attenuation coefficient. The method comprises the steps: changing the sound velocity and the tissue sound attenuation coefficient by iteration; using a series of processing methods to obtain the optimal scanning sound velocity and tissue sound attenuation coefficient; and finally setting the obtained coefficient into parameters used by the ultrasonic imaging so as to obtain ultrasonic images with more uniform brightness, better resolution and stronger contrast. A technique for optimizing the imaging parameters of the self-adaptive medical ultrasonic system has important clinical significance in diagnosis and is suitable for the technical field of medicine.

The invention provides a probe group for detecting pathogenic/susceptible genes of hereditary cardiomyopathy/arrhythmia, and provides application of a reagent for detecting pathogenic and/or susceptible genes of the cardiomyopathy in preparing products for diagnosing the cardiomyopathy. The reagent can capture various pathogenic and/or susceptible genes of the cardiomyopathy, and at most 312 related genes can be detected simultaneously. The invention further provides a probe group for detecting the pathogenic and/or susceptible genes of the cardiomyopathy and a kit containing the probe group.The probe group and the kit containing the probe group can be used for molecular genetic diagnosis of a sick individual and family screening of the sick family members, and have important clinical significance to early intervening treatment of the mutation carriers. Meanwhile, the probe group and the kit have the advantages of being high in efficiency, multiple in detection sites, accurate, easy to operate, good in specificity, high in sensitivity, rapid, high in practicability and low in cost.

The invention discloses application of a reagent for inhibiting circ_CLASP2 (Cytoplasmic Linker Associated Protein 2) in preparation of a preparation for treating nasopharyngeal darcinoma and the preparation. A research proves that the circ_CLASP2 is inhibited in nasopharyngeal darcinoma cells, and the proliferation, invasion and metastasis of the nasopharyngeal darcinoma cells can be inhibited. Therefore, a circ_CLASP2 inhibitor is used for treating the nasopharyngeal darcinoma and has profound clinical significance and an important popularization and application prospect.